8.01 -0.14 (-1.72%)
Pre-market: 4:31AM EDT
|Bid||8.13 x 2200|
|Ask||8.16 x 1000|
|Day's range||7.50 - 8.95|
|52-week range||6.07 - 24.47|
|Beta (3Y monthly)||2.42|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||9.26|
Teva Pharmaceutical Industries Ltd. and its affiliates today announced a settlement agreement with both Cuyahoga and Summit counties of Ohio. The settlement resolves the counties’ claims and removes Teva from the Track 1 opioid litigation. Under the terms of the settlement, the Company will provide the two counties with the critical opioid treatment medication buprenorphine naloxone (sublingual tablets), known by the brand name Suboxone®, valued at $25 million (at wholesale acquisition cost) and distributed over three years to help in the care and treatment of people suffering from addiction (to be allocated at each county’s discretion) and a cash payment in the amount of $20 million, to be paid over three years.
J&J (JNJ) voluntarily recalls one lot of its baby powders, which is the subject of numerous lawsuits claiming that its talc-based products contain asbestos that causes cancer.
Futures are up somewhat in this Monday's pre-market after a sell-off Friday. Much of the sentiment going forward will rely on Q3 results and other news items.
Teva, the world's largest generic drugmaker, is recalling all unexpired stock of Ranitidine Effervescent Tablets in 150 micrograms and 300 micrograms dosages, the Medicines and Healthcare products Regulatory Agency (MHRA) said https://www.gov.uk/government/news/ranitidine-mhra-drug-alert-issued-for-teva-uk-recall.
The drug industry faces roughly 2,600 lawsuits brought by state and local governments, hospitals and other entities seeking to hold drugmakers and distributors responsible for the toll of opioid abuse. Local governments seek funds to cover costs of services in their communities. Distributors McKesson Corp, AmerisourceBergen Corp and Cardinal Health have offered to pay $18 billion in cash over 18 years, while drugmaker Johnson & Johnson would pay $4 billion in cash, two people familiar with the matter told Reuters.
Emergent's (EBS) vaccine portfolio holds great potential with the newly-acquired Narcan nasal spray progressing well. Severe rivalry remains a concern though.
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.98 in the latest trading session, marking a +0.14% move from the prior day.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that it will issue a press release on its third quarter 2019 financial results on Thursday, November 7, 2019 at 7:00 a.m. ET. Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. A live webcast of the call will also be available on Teva's website at: http://ir.tevapharm.com.
The FDA approval of the self-administration option and auto-injector of AstraZeneca's (AZN) Fasenra is supported by data from the phase III GRECO study and the phase I AMES study
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new AUSTEDO® (deutetrabenazine) data will be presented at the 32nd annual Psych Congress, October 3-6, 2019 in San Diego, California.
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) announced today the retirement of Dr. Carlo de Notaristefani, and the appointment of Eric Drapé as Executive Vice President, Global Operations. Mr. Drapé will be based out of Teva’s global headquarters in Israel. "After more than seven years leading Teva Global Operations, Carlo de Notaristefani, will retire from Teva," said Kare Schultz, Teva's President and CEO.
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.76 in the latest trading session, marking a -1.74% move from the prior day.
Mallinckrodt (MNK) gains on the execution of a settlement agreement with Cuyahoga and Summit Counties in Ohio concerning the lawsuits pending in MDL.
Teva Pharmaceutical Industries Ltd. (TEVA) closed at $6.96 in the latest trading session, marking a -1.14% move from the prior day.